ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines.
about
European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHDThe intersection of attention-deficit/hyperactivity disorder and substance abuseAddiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulantsAdvances in understanding and treating ADHDNeurofeedback Therapy for Enhancing Visual Attention: State-of-the-Art and ChallengesLong-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challengesPsychotic disorders comorbid with attention-deficit hyperactivity disorder: an important knowledge gapPrefrontal cortical and striatal transcriptional responses to the reinforcing effect of repeated methylphenidate treatment in the spontaneously hypertensive rat, animal model of attention-deficit/hyperactivity disorder (ADHD).Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorderFluoxetine potentiates methylphenidate-induced gene regulation in addiction-related brain regions: concerns for use of cognitive enhancers?Selective serotonin reuptake inhibitor antidepressants potentiate methylphenidate (Ritalin)-induced gene regulation in the adolescent striatum.Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review.European guidelines on managing adverse effects of medication for ADHD.Fluoxetine potentiation of methylphenidate-induced gene regulation in striatal output pathways: potential role for 5-HT1B receptorSimilar and Different? Subjective Effects of Methylphenidate and Cocaine in Opioid-Maintained Patients.Potentiated gene regulation by methylphenidate plus fluoxetine treatment: Long-term gene blunting (Zif268, Homer1a) and behavioral correlates.Addiction and cognition.Life-long consequences of juvenile exposure to psychotropic drugs on brain and behavior.Selective serotonin re-uptake inhibitors potentiate gene blunting induced by repeated methylphenidate treatment: Zif268 versus Homer1a.Male adolescent substance use disorder and attention-deficit hyperactivity disorder: a review of the literature.Subjective effects, misuse, and adverse effects of osmotic-release methylphenidate treatment in adolescent substance abusers with attention-deficit/hyperactivity disorder.Fluoxetine potentiation of methylphenidate-induced neuropeptide expression in the striatum occurs selectively in direct pathway (striatonigral) neurons.Substance-use disorders in adolescents and adults with ADHD: focus on treatment.Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects.Cognitive enhancement drug use among future physicians: findings from a multi-institutional census of medical students.Yoked delivery of cocaine is aversive and protects against the motivation for drug in rats.College students with ADHD: current status and future directions.Prevalence of ADHD among students of zahedan university of medical science in iran.A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities.Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.Exploring the relationship among ADHD, stimulants, and substance abuse.Abuse and dependence liability analysis of methylphenidate in the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder (ADHD): what have we learned?Gene expression profiling in the striatum of amphetamine-treated spontaneously hypertensive rats which showed amphetamine conditioned place preference and self-administration.Opposite effects of amphetamine on impulsive action with fixed and variable delays to respond.Adult ADHD and comorbid disorders: clinical implications of a dimensional approach.Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men.Do ADHD symptoms moderate the relation between positive alcohol expectancies and alcohol-related outcomes?Prevalence of self-reported nonmedical use of prescription stimulants in North Carolina Doctor of Pharmacy students.Patterns of methylphenidate use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database: main trends from 2005 to 2008.Substance use in college students with ADHD.
P2860
Q21260332-7DEDC4CE-EA9E-4E09-ABB8-43787694B76BQ22242685-64EBA6D9-1F01-440E-A57F-663241047447Q22251215-64F88B3D-669A-44D9-9B64-7B3CEC8020C0Q24601949-95F64D40-0FDA-474A-8497-721885974F1BQ26740639-3A6E4ED2-5D3D-4D24-AB32-CFB33DA97424Q26822392-4955374B-BED1-4B91-9936-41915A017768Q28081111-38D1833A-C492-4067-A6E4-28660576302EQ30582194-2F2C2FAE-C282-4DD9-B762-5087B1797746Q33160890-8A97C35F-541E-4760-9252-6F0FD75F62ADQ33691271-00A55C9F-0159-45FD-B7CB-EFCEACFC39C3Q34065820-2BAE3F14-A7E8-490E-B613-7E924FB86539Q34169007-E0CFC9BA-CCE7-4A87-BDF9-19D1C6724969Q34448884-B2CCBD03-DDD2-4909-AE09-992A18A0228CQ34602540-B330FC24-D339-41CE-931A-F897F93A4183Q34675992-9A10D3E2-7776-42E5-BC80-1E2F848A03C8Q34707811-61BD017E-0535-4FDD-83A4-92B703A77F9EQ35059937-9EC39695-EF9E-4D4B-A741-B217AB198681Q35090725-D15E62FF-F98D-48DF-9A7D-DFBD549954D6Q35096339-0D97F705-082B-4B95-95B6-434D48BF4858Q35490379-83CBF908-1763-434A-B593-23EB1C205EE7Q35625911-59899113-6C94-4ABE-AF2B-4E5E690A2E10Q36177070-29484480-D7B5-4ABA-91D8-0D94BC7DE4CAQ36344412-6B853E66-6C99-4325-8BC5-D128441C5B79Q36373539-3F3C88A7-305D-4196-AB71-02BABCF6A1C1Q37009200-76D9F2AB-2A27-473B-84A2-5B014A00B955Q37389335-B645D1C5-3605-4A7A-B483-A8D1B3CD4146Q37557205-3DF09609-42D2-4743-BA0A-94DC588DAB33Q37612944-AA88A609-E368-4FB8-8C27-C750D4FAF7ABQ37638740-52986ABE-5C50-40A3-9291-471ACEDC2F28Q37803420-66766E01-10E6-4AB9-B3BB-E7E5BDABF0B0Q38029373-4A0047A7-3F14-463C-846A-BF151FBD7BA4Q38087534-31E08856-910A-4457-B4C9-6A4038B54CF7Q39138814-4C85C31B-426F-47F8-A344-C9B1B55E6C1AQ40494422-D476787F-9B73-4D8F-92BC-E6D43BCE197DQ41495299-328BEB8D-3E2A-41E5-9E7B-CE6CA903E8BCQ42599423-D4B6C1C9-C1CB-470A-9EB6-6FB75BBE1612Q43881175-D4216299-5F8C-473B-8142-8C527F2CECC6Q44299164-6E7074A7-A177-4DD7-841C-865F52B9A79EQ45794966-9B529000-A20F-4057-8050-4167E86085FEQ46906007-6DA65414-1282-44F3-AE4E-F0678245302D
P2860
ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ADHD, substance use disorders, ...... ture and treatment guidelines.
@en
ADHD, substance use disorders, ...... ture and treatment guidelines.
@nl
type
label
ADHD, substance use disorders, ...... ture and treatment guidelines.
@en
ADHD, substance use disorders, ...... ture and treatment guidelines.
@nl
prefLabel
ADHD, substance use disorders, ...... ture and treatment guidelines.
@en
ADHD, substance use disorders, ...... ture and treatment guidelines.
@nl
P2860
P356
P1476
ADHD, substance use disorders, ...... ture and treatment guidelines.
@en
P2093
Scott H Kollins
P2860
P304
P356
10.1177/1087054707311654
P577
2008-01-11T00:00:00Z